Phibro Q3 net sales rise 32% to $347.8 million; FY2025 guidance updated
Phibro reported results for the fiscal third quarter ended March 31, 2025, with net sales up 32% to $347.8 million, driven largely by the Zoetis MFA portfolio acquired October 31, 2024. The company also updated its fiscal 2025 guidance, forecasting net sales of $1.26 billion to $1.29 billion and adjusted EBITDA of $177 million to $183 million. Net income and diluted EPS both rose, while management said tariffs may affect certain inputs and sales in the next fiscal year.
Key points
- Net income $20.9 million vs. $8.4 million a year earlier; diluted EPS $0.51 vs. $0.21
- Adjusted EBITDA $54.9 million, up 85%; gross margin 30.1%, down 10 basis points
- FY2025 guidance: net sales $1.26 billion to $1.29 billion; adjusted EBITDA $177 million to $183 million; diluted EPS $0.98 to $1.11
- Webcast and conference call scheduled for Thursday, May 8, 2025 at 9:00 AM Eastern
The filing
Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.